A recent study shows that the combination of enzalutamide and talazoparib reduces the risk of progression or death by 52% in patients with metastatic prostate cancer with specific genetic alterations. This advance offers a more effective option against an aggressive cancer, although it requires genomic testing to identify suitable candidates.
How the genomic target works in this treatment 🧬
Enzalutamide blocks androgen receptors, while talazoparib inhibits DNA repair in tumor cells with mutations in genes such as BRCA. The combination simultaneously attacks two cancer survival pathways. The study, published in a specialized journal, included patients with alterations in DNA repair genes. Identifying these markers through biopsy or blood analysis is key to accessing the benefit.
The genomic test: the new procedure you didn't expect 🧪
Now, in addition to dealing with medical bureaucracy, you have to undergo a genomic test to find out if you are a candidate. Because, of course, precision medicine is great, but there's always another analysis to go through. That said, if the result is positive, the reward is a 52% reduction in risk. Almost like winning the lottery, but with less champagne and more pills.